CBIO SCHEDULE 13G/A: SEC filing

Filed with the SEC on · accession 0001738048-26-000090

CBIO filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. Venrock Healthcare Capital Partners entities and associated individuals filed an amended Schedule 13G reporting beneficial ownership of approximately 5.9% of Crescent Biopharma's ordinary shares, including shares underlying pre-funded warrants. The stock moved -4.6% by the first close after the filing.

Summary of the filing

Venrock Healthcare Capital Partners entities and associated individuals filed an amended Schedule 13G reporting beneficial ownership of approximately 5.9% of Crescent Biopharma's ordinary shares, including shares underlying pre-funded warrants. The filing is a passive investment disclosure with no intent to influence control.

Key details

Aggregate ordinary shares beneficially owned (including pre-funded warrants)$2.2M
Percentage of class beneficially ownedPCT 6
Reporting person / beneficial ownerVenrock Healthcare Capital Partners III, L.P.
Reporting person / beneficial ownerVHCP Co-Investment Holdings III, LLC
Reporting person / beneficial ownerVenrock Healthcare Capital Partners EG, L.P.
General partner / manager of reporting entitiesVHCP Management III, LLC
General partner of reporting entityVHCP Management EG, LLC
IssuerCrescent Biopharma, Inc.
Voting member of vhcp management iii and vhcp management egNimish Shah
Voting member of vhcp management iii and vhcp management egBong Y. Koh
Authorized signatory / attorney-in-factSherman G. Souther

How CBIO stock reacted

Close before

$14.15

Nov 13, 2026

First close after

-4.59%

$13.50

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for CBIO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for CBIO?

Click here

Frequently asked questions

What did CBIO file with the SEC on Nov 16, 2026?

CBIO filed a SCHEDULE 13G/A (SEC filing). Venrock Healthcare Capital Partners entities and associated individuals filed an amended Schedule 13G reporting beneficial ownership of approximately 5.9% of Crescent Biopharma's ordinary shares, including shares underlying pre-funded warrants. The filing is a passive investment disclosure with no intent to influence control.

How do I read a SCHEDULE 13G/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).

How did CBIO stock react to this filing?

CBIO closed at $14.15 before the filing and $13.50 on Nov 16, 2026 (-4.59%).

Other CBIO SEC filings

Get alerts when CBIO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days